Guillermo de Velasco
@g_develasco
Followers
6K
Following
8K
Media
157
Statuses
4K
Medical oncologist. University Hospital 12deOctubre. #bladder #kidney #prostate #immuno-oncology The nuance is not without
Joined June 2012
🚨 When EV/pembro is not an option, what's the best first-line strategy for cisplatin-ineligible patients with advanced urothelial carcinoma? 🧪 The SOGUG-AUREA study evaluated split-dose cisplatin + atezolizumab in this setting 📄
ascopubs.org
PURPOSEImmune checkpoint inhibitors combined with platinum-based chemotherapy is standard in patients with advanced/metastatic urothelial carcinoma (mUC). Cisplatin has immunomodulatory benefits...
2
17
31
JUST IN: The 2025 @NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
2
39
184
@SMEOMX #smeo2025 Carcinoma urotelial metástasico!! Con el gran experto @PGrivasMDPhD @brian_rini @RodRogSan 🔴javelin 100- IÓ mantenimiento 🟢CheckMate 901 cisplatino elegible 🟠EV + pembro amplios criterios (SG 33 vs 15 m) 🔜Como tratar post EV+pem
1
3
10
كبسولة الصحية / خبراء: دمج HDR مع الإشعاع الخارجي يحقق نتائج سريرية استثنائية لسرطان البروستاتا - عبر نبض @NabdApp
https://t.co/F7e8zpf01t تشرفت بحضور المؤتمر السادس لجمعية الأورام الإماراتية في دبي بناءً على دعوة كريمة من الزملاء. كان المؤتمر بالفعل اجتماع متميز جمع نخبة
5
9
24
Proud to call @alshamsi2000 and @ProfSyedHussain my friends and to share these moments at the @SocietyEmirates Conference #EOS25. Equally proud to see colleagues like #RaulMárquez grow and achieve so much over the past years. Surround yourself with people who lift you up it makes
2
8
28
Great meeting @SMEOMX #SMEO2025 @BourlonMaite @ReginaBarCar with excellent speakers, questions, discussion, happy to represent @fredhutch global level! Need to practice my Spanish! @drenriquegrande @g_develasco @Ecastromarcos @OncoAlert
@HutchPresident @VenurVyshak @VenurVyshak
@SMEOMX #smeo2025 Carcinoma urotelial metástasico!! Con el gran experto @PGrivasMDPhD @brian_rini @RodRogSan 🔴javelin 100- IÓ mantenimiento 🟢CheckMate 901 cisplatino elegible 🟠EV + pembro amplios criterios (SG 33 vs 15 m) 🔜Como tratar post EV+pem
1
5
22
1
20
71
Witnessed the incredible energy of the @myESMO Scientific Chairs this year. @DrChoueiri & @MyriamChalabi have put together a dazzling program. Check out the #ESMO25 Presidential Session titles 👇
1
12
34
⭐️ Huge congratulations to the one & only @PGrivasMDPhD on being named 👉🏼Medical Director of International Program & Local/Regional Outreach @fredhutch ! A visionary leader living in Seattle whose impact knows no borders- & already doing amazing things - this role couldn’t be
7
10
76
Climb for Kidney cancer event @CleClinicUro is outstanding way to support and honor our patients and support research for #cancerhope .. incredible day all thanks to @cjweight #kidneycancer
1
2
22
Terrific talk from @ReginaBarCar @incanMX on the current state of #kidneycancer in #Mexico. Very unique demographics, and very limited availability of MDT for #urologic cancers.
0
6
17
0
4
20
Global voices, shared hope. Excited to join colleagues at VIRO 2025, working together for patients in renal cancer. Please join us: Free Registration link: https://t.co/5mIBcWKg09
#OncoDaily #VIRO2025 @oncodaily
0
9
26
From Argentina to Singapore, #IUCS25 brings together voices from many corners of the globe. #Oncology is a team sport—and this summit proves it. 🌐 #GlobalOncology @gbanna74 @ravikanesvaran @neerajaiims @PGrivasMDPhD
💫🌟El Programa Científico de #IUCS25 está DISPONIBLE!💡⚡️ @urologysummit @OncoAlert @OncoReporte 🌟🎓Muy agradecida y entusiasmada de formar parte de este espacio con colegas excepcionales, donde compartiremos avances científicos y mejores prácticas en uro-oncología para el
0
14
28
👏 Congratulations to @DrFelixGuerrero from @H12Octubre for this valuable collaboration between Urology & Oncology. A clear example of unity driving progress @cdanicas
🚨Interim results of SR-4 study published in @TheLancetOncol 📉pCR rate 42% 🔗Download it here: https://t.co/vrOk5UdIeF 🤩Glad to co-author this paper with @AndreaNecchi @BerUrologia @tompowles1 @BenjaminPradere among others!
2
6
24
Excited to share our new paper @EurUrolOncol! 🎉 We developed patient-centered, stage-specific FKSI-23 tools to better capture HRQOL in localized & metastatic RCC, moving beyond generic instruments to what truly matters to patients @tompowles1 @montypal
https://t.co/2sTCZRdIjH
9
37
128
IMvigor011 𝗰𝘁𝗗𝗡𝗔+ → 𝗢𝗦/𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝘄𝗶𝘁𝗵 𝗮𝘁𝗲𝘇𝗼 𝗰𝘁𝗗𝗡𝗔– → 𝘀𝗽𝗮𝗿𝗲𝗱 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗜𝗢 Primum non nocere: treating only those with molecular evidence of disease. This is Huge! Congrats to @tompowles1 and everyone involved 👏
IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last https://t.co/dPqlvr2rnV
0
15
43
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
merck.com
First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in...
0
6
19
JUST IN: (+) Phase 3 KEYNOTE-905 trial in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): EV+Pembro shows an EFS, pCR and OS benefit compared to radical cystectomy alone. a Potential new SOC (again). cc: @biospace
https://t.co/qVaDh0I3GN
1
54
128
🚨 JUST PUBLISHED in @JCM_MDPI @MDPIOpenAccess 🔬 Detailed overview of the current research landscape in perioperative #MIBC 🤓 Read it: https://t.co/M6jpqOAoAA
@MarioHArroyo @cgdelcanizo @cdanicas @g_develasco @H12Octubre @Urologia12 @bvh12o @GuardConsortium @CANVES_ES @GUOaeu
0
9
26